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The mechanism by which lutein, a carotenoid, acts as an antioxidant in retinal cells is still not fully
understood. Here, lutein treatment of a neuronal cell line (PC12D) immediately resulted in reduced intra-
cellular ROS levels, implying that it has a direct role in ROS scavenging. Signiﬁcantly, lutein treatment also
induced phase II antioxidative enzyme expression, probably via a nuclear factor-like 2 (Nrf2) independent
pathway. This latter mechanism could explain why lutein acts diversely to protect against oxidative/cyto-
toxic stress, and why it is physiologically involved in the human neural tissue, such as the retina.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction of ROS scavengers exist, for example, carotenoids and ﬂavonoidsIn addition to pharmacotherapeutics, a variety of nutritional
interventions are currently under investigation as novel
approaches for the suppression of disease progression and/or tis-
sue/organ damage.
Both in vivo and in vitro experiments suggest that inﬂammatory
processes are involved in disease pathogenesis [1]. Recent studies
focused on the link between inﬂammation and intracellular oxida-
tive stress by reactive oxygen species (ROS). Although ROS are con-
stantly generated in mitochondria and peroxisomes as a result of
physiological metabolism [2], excessive ROSmay induce inﬂamma-
tion, oxidizing lipids, proteins and nucleic acids [3], thereby causing
tissue/organ disorders. Excessive oxidative stress is involved in
neurodegenerative diseases [4–6], cardiovascular diseases [7], and
cancer [8]. Thus, it is proposed that prevention or inhibition of
inﬂammatory processes can be achieved by suppressing excessive
ROS using antioxidative products.
The body produces antioxidative molecules, such as glutathione
[9] and bilirubin [10]. Additionally, plant-derived dietary sources[11–14]. Among these, lutein, a carotenoid, is selectively concen-
trated in the retina where it forms macular pigment, a physiologi-
cal component of the eye. The clinical signiﬁcance of retinal lutein
is suggested by human data. Low level of macular pigments, i.e. a
low lutein concentration in the macula, is reported to be a risk fac-
tor for the development of age-related macular degeneration
(AMD), a leading cause of blindness [15]. Moreover, autopsy re-
ports reveal that eyes from AMD patients have 30% lower levels
of macular pigment than age-matched controls [16]. Because the
retina has a higher oxygen requirement compared to most other
organs [17], it is susceptible to oxidative stress; hence, low levels
of retinal lutein could lead to ROS accumulation, resulting in local
inﬂammation and the induction of AMD. Lutein forms a yellow pig-
ment and is thus thought to play a secondary role in ﬁltering blue
light in the retina [18]. This mechanismmay also protect the retina
from light-induced oxidative damage.
Over the past decade, a role for carotenoids and their deriva-
tives in the activation and modulation of transcription systems
has been revealed [19,20]. Recently, in inﬂammatory cells, lutein
was reported to induce expression of matrix metalloprotease 9
via a nuclear receptor [21]. Thus, there may be a possibility that lu-
tein acts to reduce oxidative stress not only via ROS scavenging
and/or via the physical blockage of blue light. Phase II antioxidant
enzymes (including heme oxygenase-1 [HO-1], superoxide dismu-
tase 1 and 2 [SOD1 and 2], catalase, peroxiredoxin 1 [Prdx1], and
NAD(P)H dehydrogenase, quinone 1 [NQO1]) are induced in re-
sponse to stress stimuli, and their expression is regulated by the
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whether lutein can induce gene expression of such an antioxidant
defense system is still unknown.
The purpose of this study, therefore, was to investigate the
involvement of lutein in the regulation of antioxidative enzyme
expression.
2. Materials and methods
2.1. Cell culture
Rat adrenal pheochromocytoma cell line, PC12D, was main-
tained in high-glucose Dulbecco’s modiﬁed Eagle’s medium
(DMEM) (D5796) (Sigma–Aldrich, St. Louis, MO, USA) supple-
mented with 10% fetal bovine serum (FBS) (Life technologies, Carls-
bad, CA, USA), 10% horse serum (HS) (Life technologies), penicillin
(100 units/ml) and streptomycin (100 lg/ml) at 37 C under a
humidiﬁed atmosphere of 5% CO2. For subculture, PC12D cells were
harvested at 80–90% conﬂuence.
2.2. Differentiation into neuronal cells
Cells were seeded on tissue culture plates coated with 0.1% gel-
atin and containing complete medium without antibiotics. After
24 h, cell culture medium was changed to DMEM containing 0.5%
FBS and 50 ng/ml nerve growth factor (NGF) (Upstate Biotechnol-
ogy, Lake Placid, NY, USA) and maintained at 37 C for 48 h under
a humidiﬁed atmosphere of 5% CO2 to induce differentiation.
2.3. Emulsiﬁcation of lutein using non-ionic surfactant
Lutein was sourced from lutein-rich marigold extract (LME)
containing 85% lutein (provided by WAKASA SEIKATSU, CO., Ltd.,
Kyoto, Japan). Lutein emulsiﬁcation was as described elsewhere
[23]. Brieﬂy, LME was micellated in an ethanol (Wako pure chem-
ical, Osaka, Japan)/Tween 80 (Sigma–Aldrich) solution
(310 ll:10 ll), and concentrated under N2 gas to make a 500 mM
stock solution in 10 ll of Tween 80. The stock solution was serially
diluted to make a working solution (50 lM lutein and 0.01% Tween
80 in DMEM with 0.5% FBS without antibiotics), prior to applica-
tion to PC12D cells. The control vehicle was consisted of 0.01%
Tween 80 in DMEM with 0.5% FBS without antibiotics.
2.4. ROS measurement
Intracellular ROS levels were determined using the ﬂuorescent
dye, CM-H2DCFDA (Invitrogen, Carlsbad, CA, USA). A 2 mM stock
solution of CM-H2DCFDA was reconstituted in anhydrous dimethyl
sulfoxide (DMSO Sigma–Aldrich), and 2 ll was added to the cul-
ture 30 min before the measurement at each time point. After incu-
bation for 30 min at 37 C, ﬂuorescence was measured (excitation
wavelength, 485 nm; emission wavelength, 528 nm) using the
ﬂuorescence microplate reader, Synergy 4 (BioTek Instruments,
Inc., Winooski, VT, USA). The area scanning read mode was selected
to obtain averaged intensity over the entire area of the well.
2.5. Real-time PCR
Total RNA was extracted from cells using TRIzol reagent (Life
technologies). Complementary DNA was synthesized using Super-
Script VILO™ Master Mix (Life technologies) according to the
manufacturer’s instruction. PCR was performed using the StepOne-
Plus Real Time PCR system (Life technologies). The mRNA levels
were evaluated by the DDCT method, and normalized to GAPDH
mRNA. The primers are shown in Supplementary Table 1.2.6. Whole cell lysate preparation and protein extraction from nuclear
and cytoplasmic fractions
Differentiated cells were resuspended in lysis buffer (10 mM
Tris–HCl (pH 7.6), 1% TritonX-100, 50 mM NaCl, 1 mM EDTA,
1 mM EGTA, 29 mM sodium pyrophosphate decahydrate,
47.6 mM sodium ﬂuoride, 19 mM b-glycerophosphate disodium
salt hydrate) containing protease inhibitor cocktail (Complete,
EDTA-free; Roche, Mannheim, Germany) and phosphatase inhibi-
tor cocktail 2 and 3 (Sigma–Aldrich), sonicated, and left on ice
for 30 min. After centrifugation, the supernatant containing the
whole cell lysate was transferred to a new 1.5 ml tube and kept
and stored at 80 C until use.
The nuclear and cytoplasmic fractions were separated using the
NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher
Scientiﬁc Inc., IL, USA) according to the manufacturer’s instruction.
Protein concentration was determined using the Quick Start™
Bradford 1 Dye Reagent (BIO-RAD Laboratories, Hercules, CA,
USA) with Quick Start™ Bovine Gamma Globulin (BIO-RAD) as a
standard.
2.7. Immunoblot analyses
Samples of cell extract were separated by SDS–polyacrylamide
gel electrophoresis, and the proteins were transferred to a polyvi-
nylidene ﬂuoride membrane (Immobilon-P; Millipore, Bedford,
MA, USA) in a Trans-Blot SD Cell (BIO-RAD). The membrane was
blocked with blocking buffer (0.1 M Tris–HCl, pH 7.5, 0.15 M NaCl,
0.5% TSA Blocking Reagent [PerkinElmer Life Sciences, Waltham,
MA, USA]), incubated overnight at 4 C with either of the primary
antibodies (Supplementary Table 2), and then incubated with
horseradish peroxidase-conjugated secondary antibody (1/2,000;
Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA)
for 1 h. The signals were detected using ECL Western Blotting
Detection Reagents (GE healthcare Limited, Buckinghamshire,
HP8 4SP, UK). Signal intensities were quantiﬁed using the ImageJ
program [24], and normalized to that of GAPDH. For nuclear and
cytoplasmic Nrf2 analyses, protein was loaded at 2.5 and 5 lg,
respectively, immunoblotted using Nrf2 antibody (Supplementary
Table 2), and nuclear and cytoplasmic Nrf2 were detected and
quantiﬁed as above.
2.8. Statistical analyses
Values were expressed as the mean ± s.d. ANOVA followed by
Tukey’s post hoc test was used to assess the statistical signiﬁcance
of the difference among 4 groups (Fig. 1) and Student’s t-test was
used to assess the difference between 2 groups (Figs. 2–4).
P < 0.05 was regarded as signiﬁcant.3. Results
3.1. Lutein reduces ROS in PC12D neuronal cells
To investigate the ROS removal function of lutein, ROS levels
were monitored in differentiated PC12D neuronal cells by measur-
ing changes in CM-H2DCFDA ﬂuorescence intensity. Fluorescence
intensity was lower in lutein-treated cells than in vehicle-treated
cells as early as 1 h after treatment, and remained low for up to
24 h after treatment (Fig. 1). For positive control of the experiment,
H2O2 was added 5 min before each time point, and the increase in
the ﬂuorescence intensity was conﬁrmed. For negative control, no
CM-H2DCFDA probe was added. The intensities were shown rela-
tive to that of vehicle-treated cells measured 1 h after treatment.
The levels were relatively high at earlier time points most probably
Fig. 1. Lutein reduced ROS levels in PC12D neuronal cells. ROS levels were
measured using an oxidative stress indicator, CM-H2DCFDA, in differentiated
PC12D cells treated with vehicle (V) or lutein (L). For positive control, H2O2 (50 lM)
was added 5 min before the measurement. For negative control, no probe of CM-
H2DCFDA was added. The levels of ROS relative to the vehicle-treated cells
measured 1 h after treatment were shown. At any time points, ROS level of positive
control was higher, and that of lutein-treated cells were lower, than the vehicle-
treated cells, and the value with no probe showed the lowest level, all in a
statistically signiﬁcant manner analyzed by ANOVA followed by Tukey’s post hoc
test. n = 6. ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001; n.s., not signiﬁcant.
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signiﬁcant by the analysis using ANOVA followed by post hoc test
that at any time points, positive control showed the highest, vehi-
cle-treated cells showed the second highest, and the lutein-treated
cells showed the lowest levels. This result suggests that lutein can
scavenge ROS in differentiated PC12D cells.3.2. Effect of lutein on phase II enzyme mRNA levels
Phase II genes encoding detoxifying and antioxidant enzymes
are induced in response to ROS [25]. Thus, we examined the levels
of phase II gene mRNAs in lutein- or vehicle-treated differentiatedFig. 2. Effect of lutein on phase II enzyme mRNA levels Real-time PCR showing that phas
(L)- than after vehicle (V)-treatment. The mRNA level of HO-2, which is not a phase II enz
Superoxide dismutase 1; SOD2, Superoxide dismutase 2; Prdx1, Peroxiredoxin-1; NQ
signiﬁcant.PC12D cells. At 24 h after lutein treatment, the mRNA levels of HO-
1, SOD1, SOD2, catalase, Pdrx1, and NQO1 were all higher than in
vehicle-treated cells. By contrast, HO-2, which is constitutively
expressed under homeostatic conditions and is not a phase II en-
zyme, was not induced (Fig. 2). Hence, lutein treatment induced
phase II enzyme mRNA expression in differentiated PC12D neuro-
nal cells despite the lower levels of ROS in these cells.
3.3. Effect of lutein on phase II enzyme protein levels
To determine whether phase II enzyme protein levels were also
higher in lutein-treated cells than in vehicle-treated cells, we per-
formed immunoblot analyses (Fig. 3). The protein levels of HO-1,
SOD2, and NQO1 were all signiﬁcantly higher in lutein-treated
cells than in vehicle-treated cells at 24 h, while the levels of HO-
2, SOD1, catalase, and Prdx1 remained the same.
3.4. Effect of lutein on the Nrf2 pathway
Phase II enzyme-encoding genes are induced by Nrf2 transcrip-
tion factor binding to the antioxidant response element (ARE) or
the electrophile response element (EpRE) in the promoter regions
of these genes [26]. Immunoblot analyses were performed to
investigate whether nuclear transport of Nrf2 is induced in differ-
entiated PC12D neuronal cells after lutein treatment. Nuclear Nrf2
levels were unchanged (Fig. 4A) and Nrf2 was virtually undetect-
able in the cytoplasmic fraction (data not shown) over the time
course of lutein treatment. Upstream pathways of Nrf2 (speciﬁ-
cally the PI3K/AKT/GSK-3b and MAPKs pathways) can affect nucle-
ar translocation of Nrf2 [27]. Hence, the phosphorylation (activated
state) of GSK-3b at Tyr216, MEK1/2, p44/42 MAPK (Erk1/2), and
p38 MAPK (p38) was examined in whole cell lysates at 24 h; how-
ever, no increase in the ratios of the activated forms were observed
(Fig. 4B). Thus, lutein treatment does not appear to activate Nrf2 or
its corresponding upstream pathways.e II enzyme mRNA levels in differentiated PC12D cells were higher 24 h after lutein
yme, was not changed. HO-1, Heme oxygenase-1; HO-2, Heme oxygenase-2; SOD1,
O1, NA(D)PH dehydrogenase, quinone 1. n = 4. ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001; n.s., not
Fig. 3. Effect of lutein on phase II enzyme protein levels Immunoblot analyses revealed that the protein levels of HO-1, SOD2, and NQO-1 in differentiated PC12D cells were
higher at 24 h after lutein (L)- than after vehicle (V)-treatment. n = 4. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001; n.s., not signiﬁcant.
Fig. 4. Effect of lutein on the Nrf2 pathway Immunoblot analyses. (A) There were no differences in the relative nuclear Nrf2 protein levels between lutein (L)- and vehicle (V)-
treated differentiated PC12D cells at the time points indicated. (B) Relative protein levels of phosphorylated versus unphosphorylated forms of GSK-3b, MEK1/2, Erk1/2, and
p38 in whole cell lysate indicated no increase in the phosphorylated, activated forms of these proteins. Phosphorylation of GSK-3bwas checked by detecting phosphorylation
at the Tyr216 residue with a phospho-speciﬁc antibody. n = 4. ⁄⁄P < 0.01; n.s., not signiﬁcant.
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In this study, we demonstrated that an antioxidant, lutein, re-
duced ROS levels in a neuronal cell culture derived from PC12D cell
lines (Fig. 1). Lutein also induced the expression of phase II en-
zymes (Fig. 2), both at the mRNA and protein levels (Fig. 3). How-
ever, interestingly, lutein treatment did not activate the activator
of phase II enzyme genes, Nrf2, and its upstream pathways (Fig. 4).In general, phase II enzymes are upregulated in response to
oxidative stress [28], via Nrf2 binding to the ARE [29]. Keap1-
mediated proteasomal degradation of cytoplasmic Nrf2 is sup-
pressed by ROS, which disrupt Nrf2-Keap1 binding by modifying
cysteine residues in Keap1 [27]. Free Nrf2 translocates to the nu-
cleus, binds to ARE, and initiates transcription of a large array of
cytoprotective genes. Previous observations indicated that Nrf2
plays a key role in regulating ARE-driven genes. Overexpression
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gene expression in response to heme and heavy metals [29], and
Nrf2-null mice were more susceptible to oxidative/electrophilic
stress-induced liver pathologies than wild-type mice [30]. How-
ever, in this study, phase II gene induction was not preceded by
an increase in ROS levels, and rather, it was preceded by a decrease
in ROS levels. Moreover, basal levels of Nrf2 did not increase in the
nucleus in response to lutein treatment, and upstream pathways
that induce Nrf2 nuclear translocation were similarly unaffected.
The PI3K/AKT/GSK3b and MAPK pathways are involved in
numerous reactions upstream of Keap1 interaction that regulate
Nrf2 levels via post-transcriptional modiﬁcation. In response to
oxidative stress, GSK-3b is activated by phosphorylation at
Tyr216 and in turn, activates cytosolic Fyn, allowing their nuclear
translocation [31,32] and the subsequent phosphorylation of Nrf2
at Tyr568. Nrf2 phosphorylated at Tyr568 is then exported from
the nucleus [27], binds to Keap1, and is degraded [33].
Conversely, a member of the MAPK family, Erk1/2, which is acti-
vated by MEK1/2, phosphorylates serine/threonine residues on
Nrf2 to promote its translocation into the nucleus [34]. Butylated
hydroxyanisole (BHA), although it is an antioxidant, activates this
pathway, eventually increasing HO-1 expression through the ARE
[35]. Meanwhile, another MAPK, p38, phosphorylates Nrf2, result-
ing in its association with Keap1 thereby preventing its nuclear
translocation [27]. p38 overexpression also attenuates the action
of sulforaphane, a plant-derived Nrf2 inducer, which activates
the ARE-rich enhancer region of HO-1 [36]. Hence, the phosphory-
lation state of different residues on Nrf2 is a determining factor in
the regulation of nuclear Nrf2 levels and subsequent ARE-depen-
dent gene expression.
In this study, the levels of phosphorylated GSK3b, MEK1/2, Erk1/
2, and p38 were not increased after lutein treatment. Moreover,
phosphorylated and activated MEK1/2 and Erk1/2 were
signiﬁcantly decreased. Because MEK1/2 can be activated by oxida-
tive stress [37], reduction in ROS level by lutein treatmentmay have
reduced the levels of phosphorylated MEK1/2, and subsequently,
phosphorylated Erk1/2. Consistently, nuclear Nrf2 levels remained
unchanged. These ﬁndings suggest a role for lutein in an Nrf2-inde-
pendent phase II enzyme inducing pathway. We explored the po-
tential involvement of retinoid acid receptor (RAR) activity in this
pathway, since RAR is activated by another carotenoid, b-crypto-
xanthin [38]. However, the induction of phase II enzyme transcrip-
tion was unaffected by RAR inhibitors or by its putative co-acting
molecule, retinoid X receptor (RXR) (data not shown), suggesting
the involvement of other currently undeﬁned pathways.
The potential involvement of another cytoprotective pathway
for lutein that induces phase II enzymes, with the potential to re-
duce oxidative stress and cytotoxic signals, is signiﬁcant. This ﬁnd-
ing will pave the way to explaining why lutein is involved in the
neural tissue, the retina, and why lutein can protect against both
excessive light exposure [39] and diverse oxidative/inﬂammatory
stresses [40,41].
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